Compare · ALNY vs LONA
ALNY vs LONA
Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and LeonaBio Inc. (LONA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ALNY focuses on Biotechnology: Pharmaceutical Preparations, while LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ALNY is the larger of the two at $19.80B, about 615.5x LONA ($32.2M).
- ALNY has been more active in the news (23 items in the past 4 weeks vs 7 for LONA).
- ALNY has more recent analyst coverage (25 ratings vs 4 for LONA).
- Company
- Alnylam Pharmaceuticals Inc.
- LeonaBio Inc.
- Price
- -
- -
- Market cap
- $19.80B
- $32.2M
- 1M return
- -35.63%
- -
- 1Y return
- -67.18%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2020
- News (4w)
- 23
- 7
- Recent ratings
- 25
- 4
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Latest ALNY
- Alnylam to Webcast Presentations at Upcoming December Investor Conferences
- Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
- Chief Executive Officer Yvonne Greenstreet gifted 11,000 shares, decreasing direct ownership by 11% to 84,802 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Alnylam Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.
- Director Pyott David E I exercised 3,780 shares at a strike of $71.99, increasing direct ownership by 239% to 5,362 units (SEC Form 4)
- Director Sigal Charles Elliott bought $243,600 worth of shares (1,600 units at $152.25) (SEC Form 4)
- Director Schulman Amy W bought $299,526 worth of shares (1,910 units at $156.82), increasing direct ownership by 8% to 25,959 units (SEC Form 4)
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
Latest LONA
- LeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- Large owner Portman David J. bought $9,919,161,281 worth of shares (3,149,470 units at $3,149.47) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.
- SEC Form 4 filed by LeonaBio Inc.
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Portman David J.
- LeonaBio to Participate in Cantor Global Healthcare Conference 2026